Jazz PharmaceuticalsHAM:J7Z +4.91%73 Gross Margin % is 87.45% as of Mar. 2026, which is 4% below its 10-year median of 90.99. GuruFocus rates HAM:J7Z with a GF Score™ of 73/100 and a GF Value™ of €127.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 735 Biotechnology companies, Jazz Pharmaceuticals ranks better than 80.82% on this metric.
The historical rank and industry rank for Jazz Pharmaceuticals's Gross Margin % or its related term are showing as below:
HAM:J7Z'
s Gross Margin % Range Over the Past 10 Years
Min: 85.23 Med: 90.99 Max: 94.08
Current: 88
During the past 13 years, the highestGross Margin % of Jazz Pharmaceuticals was 94.08%. The lowest was 85.23%. And the median was 90.99%.
HAM:J7Z's Gross Margin % is ranked better than 80.82% of 735
companies
in the Biotechnology industry
Industry Median: 60.9
vs HAM:J7Z: 88.00
Jazz Pharmaceuticals had a gross margin of 87.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Jazz Pharmaceuticals was -0.40% per year.
Jazz Pharmaceuticals (HAM:J7Z) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jazz Pharmaceuticals had a gross margin of 87.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jazz Pharmaceuticals Gross Margin % Related Terms
Jazz Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:J7Z vs BBIO, EXEL, IONS: Gross Margin % Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jazz Pharmaceuticals (HAM:J7Z) has a Gross Margin % of 87.45% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Jazz Pharmaceuticals and its competitors. This is near median its historical median of 90.99. Over the past decade, Jazz Pharmaceuticals' Gross Margin % has ranged from 85.23 to 94.08. According to the industry distribution chart, Jazz Pharmaceuticals ranks #141 out of 735 companies in the Biotechnology industry, placing it in the top 19.2%.
Is Jazz Pharmaceuticals' Gross Margin % too high?
Jazz Pharmaceuticals' current Gross Margin % of 87.45% is near median its 10-year median of 90.99. Over the past 10 years, this metric has ranged from a low of 85.23 to a high of 94.08. The Biotechnology industry median Gross Margin % is 60.90. Jazz Pharmaceuticals' value of 87.45% is 43.6% above this industry median. Based on the distribution chart, Jazz Pharmaceuticals ranks #141 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Gross Margin % compare to BBIO and EXEL?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #141 out of 735 companies for Gross Margin %. This places Jazz Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Jazz Pharmaceuticals' value of 87.45% is 43.6% above this benchmark. Historically, Jazz Pharmaceuticals' own Gross Margin % has ranged from 85.23 to 94.08 over the past decade. While the company's 10-year median is 90.99 vs. the industry median of 60.90, Jazz Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jazz Pharmaceuticals's current Gross Margin % of 87.45% is 43.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jazz Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jazz Pharmaceuticals's current Gross Margin % is 87.45%, which is near median its own 10-year median of 90.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (HAM:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €127.01, compared to a current price of €209.50 — trading 64.9% above its estimated fair value. The current Gross Margin % is 87.45%, which is near median its 10-year median of 90.99 and 43.6% above the Biotechnology industry median of 60.90. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jazz Pharmaceuticals (HAM:J7Z), the current Gross Margin % is 87.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (HAM:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €209.50 is trading 64.9% above its estimated GF Value™ of €127.01.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for HAM:J7Z:
Gross Margin %: 87.45% (near median its 10-year median of 90.99)
GF Value™: €127.01 vs. price of €209.50 (64.9% above fair value)
Industry Position: 43.6% above the Biotechnology median (#141 of 735)
No single metric tells the full story. See the HAM:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for HAM:J7Z
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:J7Z has been successfully added to your 
